Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis: workshop summary
Gespeichert in:
| Körperschaft: | |
|---|---|
| Format: | Elektronisch E-Book |
| Sprache: | English |
| Veröffentlicht: |
Washington, District of Columbia
National Academies Press
[2013]
|
| Schlagworte: | |
| Beschreibung: | "Forum on drug discovery, development, and translation."--Cover. - "Workshop was held on July 31- August 1, 2012 in Washington, D.C. Includes bibliographical references (pages 111-113) To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB) a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin) face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high quality medicines to more of the people who need them. This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review: To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks ; The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain ; What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S. President's Emergency Plan for AIDS Relief [PEPFAR]) ; The current allocation of responsibilities and roles of the private (including industry and nonprofit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration ; Identification of potential innovative solutions to the problem |
| Beschreibung: | 1 Online-Ressource (170 pages) |
| ISBN: | 0309265959 9780309265959 9780309265966 |
Internformat
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV041957099 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 140707s2013 |||| o||u| ||||||eng d | ||
| 020 | |a 0309265959 |c Print |9 0-309-26595-9 | ||
| 020 | |a 9780309265959 |c Print |9 978-0-309-26595-9 | ||
| 020 | |a 9780309265966 |c Online |9 978-0-309-26596-6 | ||
| 035 | |a (OCoLC)880439901 | ||
| 035 | |a (DE-599)BVBBV041957099 | ||
| 040 | |a DE-604 |b ger |e aacr | ||
| 041 | 0 | |a eng | |
| 082 | 0 | |a 362.19699/5 |2 23 | |
| 110 | 2 | |a Workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB <2012, Washington, D.C.> |e Verfasser |4 aut | |
| 245 | 1 | 0 | |a Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis |b workshop summary |c Anna Nicholson [and three others], Rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| 264 | 1 | |a Washington, District of Columbia |b National Academies Press |c [2013] | |
| 300 | |a 1 Online-Ressource (170 pages) | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 500 | |a "Forum on drug discovery, development, and translation."--Cover. - "Workshop was held on July 31- August 1, 2012 in Washington, D.C. | ||
| 500 | |a Includes bibliographical references (pages 111-113) | ||
| 500 | |a To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB) a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin) face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. | ||
| 500 | |a A strengthened global supply chain for SLDs could save lives by consistently delivering high quality medicines to more of the people who need them. This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available. | ||
| 500 | |a Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review: To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks ; The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain ; What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S. | ||
| 500 | |a President's Emergency Plan for AIDS Relief [PEPFAR]) ; The current allocation of responsibilities and roles of the private (including industry and nonprofit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration ; Identification of potential innovative solutions to the problem | ||
| 505 | 0 | |a Logistics, Supply, and Demand -- Financing of MDR TB SLDs -- Innovative Suggestions and Potential Solutions | |
| 650 | 4 | |a Multidrug-resistant tuberculosis / Prevention / Congresses | |
| 650 | 4 | |a Business logistics / Congresses | |
| 650 | 4 | |a International cooperation / Congresses | |
| 653 | |a Electronic books | ||
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |2 gnd-content | |
| 700 | 1 | |a Nicholson, Anna |e Sonstige |4 oth | |
| 710 | 2 | |a Institute of Medicine (U.S.) |b Forum on Drug Discovery, Development, and Translation |e Sonstige |4 oth | |
| 710 | 2 | |a Institute of Medicine (U.S.) |b Board on Health Sciences Policy |e Sonstige |4 oth | |
| 912 | |a ZDB-38-EBR | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-027399987 | ||
Datensatz im Suchindex
| _version_ | 1804152341134311424 |
|---|---|
| any_adam_object | |
| author_corporate | Workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB <2012, Washington, D.C.> |
| author_corporate_role | aut |
| author_facet | Workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB <2012, Washington, D.C.> |
| author_sort | Workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB <2012, Washington, D.C.> |
| building | Verbundindex |
| bvnumber | BV041957099 |
| collection | ZDB-38-EBR |
| contents | Logistics, Supply, and Demand -- Financing of MDR TB SLDs -- Innovative Suggestions and Potential Solutions |
| ctrlnum | (OCoLC)880439901 (DE-599)BVBBV041957099 |
| dewey-full | 362.19699/5 |
| dewey-hundreds | 300 - Social sciences |
| dewey-ones | 362 - Social problems and services to groups |
| dewey-raw | 362.19699/5 |
| dewey-search | 362.19699/5 |
| dewey-sort | 3362.19699 15 |
| dewey-tens | 360 - Social problems and services; associations |
| discipline | Soziologie |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04748nmm a2200469zc 4500</leader><controlfield tag="001">BV041957099</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">140707s2013 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0309265959</subfield><subfield code="c">Print</subfield><subfield code="9">0-309-26595-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309265959</subfield><subfield code="c">Print</subfield><subfield code="9">978-0-309-26595-9</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9780309265966</subfield><subfield code="c">Online</subfield><subfield code="9">978-0-309-26596-6</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)880439901</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV041957099</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">aacr</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">362.19699/5</subfield><subfield code="2">23</subfield></datafield><datafield tag="110" ind1="2" ind2=" "><subfield code="a">Workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB <2012, Washington, D.C.></subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis</subfield><subfield code="b">workshop summary</subfield><subfield code="c">Anna Nicholson [and three others], Rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Washington, District of Columbia</subfield><subfield code="b">National Academies Press</subfield><subfield code="c">[2013]</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 Online-Ressource (170 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">"Forum on drug discovery, development, and translation."--Cover. - "Workshop was held on July 31- August 1, 2012 in Washington, D.C.</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Includes bibliographical references (pages 111-113)</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB) a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin) face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">A strengthened global supply chain for SLDs could save lives by consistently delivering high quality medicines to more of the people who need them. This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available. </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review: To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks ; The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain ; What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S. </subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">President's Emergency Plan for AIDS Relief [PEPFAR]) ; The current allocation of responsibilities and roles of the private (including industry and nonprofit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration ; Identification of potential innovative solutions to the problem</subfield></datafield><datafield tag="505" ind1="0" ind2=" "><subfield code="a">Logistics, Supply, and Demand -- Financing of MDR TB SLDs -- Innovative Suggestions and Potential Solutions</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Multidrug-resistant tuberculosis / Prevention / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Business logistics / Congresses</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">International cooperation / Congresses</subfield></datafield><datafield tag="653" ind1=" " ind2=" "><subfield code="a">Electronic books</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Nicholson, Anna</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="b">Forum on Drug Discovery, Development, and Translation</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="710" ind1="2" ind2=" "><subfield code="a">Institute of Medicine (U.S.)</subfield><subfield code="b">Board on Health Sciences Policy</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-38-EBR</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-027399987</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift gnd-content |
| genre_facet | Konferenzschrift |
| id | DE-604.BV041957099 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T01:09:10Z |
| institution | BVB |
| isbn | 0309265959 9780309265959 9780309265966 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-027399987 |
| oclc_num | 880439901 |
| open_access_boolean | |
| physical | 1 Online-Ressource (170 pages) |
| psigel | ZDB-38-EBR |
| publishDate | 2013 |
| publishDateSearch | 2013 |
| publishDateSort | 2013 |
| publisher | National Academies Press |
| record_format | marc |
| spelling | Workshop on Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant TB <2012, Washington, D.C.> Verfasser aut Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis workshop summary Anna Nicholson [and three others], Rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies Washington, District of Columbia National Academies Press [2013] 1 Online-Ressource (170 pages) txt rdacontent c rdamedia cr rdacarrier "Forum on drug discovery, development, and translation."--Cover. - "Workshop was held on July 31- August 1, 2012 in Washington, D.C. Includes bibliographical references (pages 111-113) To effectively treat patients diagnosed with drug-resistant (DR) tuberculosis (TB) and protect the population from further transmission of this infectious disease, an uninterrupted supply of quality-assured (QA), second-line anti-TB drugs (SLDs) is necessary. Patients diagnosed with multidrug-resistant tuberculosis (MDR TB) a disease caused by strains of Mycobacterium tuberculosis (M.tb.) resistant to two primary TB drugs (isoniazid and rifampicin) face lengthy treatment regimens of 2 years or more with daily, directly observed treatment (DOT) with SLDs that are less potent, more toxic, and more expensive than those used to treat drug-susceptible TB. From 2000 to 2009, only 0.2-0.5 percent of the estimated 5 million MDR TB cases globally were treated with drugs of known quality and in programs capable of delivering appropriate care (Keshavjee, 2012). The vast majority of MDR TB patients either died from lack of treatment or contributed to the spread of MDR TB in their communities. A strengthened global supply chain for SLDs could save lives by consistently delivering high quality medicines to more of the people who need them. This public workshop explored innovative solutions to the problem of how to get the right SLDs for MDR TB to people who critically need them. More specifically, the workshop examined current problems and potential opportunities for coordinated international efforts to ensure that a reliable and affordable supply of high-quality SLDs is available. Developing and Strengthening the Global Supply Chain for Second-Line Drugs for Multidrug-Resistant Tuberculosis: Workshop Summary covers the objectives of the workshop, which were to review: To what extent and in what ways current mechanisms are or are not effectively accomplishing what is needed, including consideration of bottlenecks ; The advantages and disadvantages of centralization in the management of the global drug supply chain, and potential decentralized approaches to improve operations of the supply chain ; What can be learned from case studies and examples from other diseases (e.g., the Affordable Medicines Facility-malaria (AMFm) and the U.S. President's Emergency Plan for AIDS Relief [PEPFAR]) ; The current allocation of responsibilities and roles of the private (including industry and nonprofit public health organizations) and public sectors, and examination of opportunities for enhancing and optimizing collaboration ; Identification of potential innovative solutions to the problem Logistics, Supply, and Demand -- Financing of MDR TB SLDs -- Innovative Suggestions and Potential Solutions Multidrug-resistant tuberculosis / Prevention / Congresses Business logistics / Congresses International cooperation / Congresses Electronic books (DE-588)1071861417 Konferenzschrift gnd-content Nicholson, Anna Sonstige oth Institute of Medicine (U.S.) Forum on Drug Discovery, Development, and Translation Sonstige oth Institute of Medicine (U.S.) Board on Health Sciences Policy Sonstige oth |
| spellingShingle | Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis workshop summary Logistics, Supply, and Demand -- Financing of MDR TB SLDs -- Innovative Suggestions and Potential Solutions Multidrug-resistant tuberculosis / Prevention / Congresses Business logistics / Congresses International cooperation / Congresses |
| subject_GND | (DE-588)1071861417 |
| title | Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis workshop summary |
| title_auth | Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis workshop summary |
| title_exact_search | Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis workshop summary |
| title_full | Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis workshop summary Anna Nicholson [and three others], Rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_fullStr | Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis workshop summary Anna Nicholson [and three others], Rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_full_unstemmed | Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis workshop summary Anna Nicholson [and three others], Rapporteurs ; Forum on Drug Discovery, Development, and Translation, Board on Health Sciences Policy, Institute of Medicine of the National Academies |
| title_short | Developing and strengthening the global supply chain for second-line drugs for multidrug-resistant tuberculosis |
| title_sort | developing and strengthening the global supply chain for second line drugs for multidrug resistant tuberculosis workshop summary |
| title_sub | workshop summary |
| topic | Multidrug-resistant tuberculosis / Prevention / Congresses Business logistics / Congresses International cooperation / Congresses |
| topic_facet | Multidrug-resistant tuberculosis / Prevention / Congresses Business logistics / Congresses International cooperation / Congresses Konferenzschrift |
| work_keys_str_mv | AT workshopondevelopingandstrengtheningtheglobalsupplychainforsecondlinedrugsformultidrugresistanttb2012washingtondc developingandstrengtheningtheglobalsupplychainforsecondlinedrugsformultidrugresistanttuberculosisworkshopsummary AT nicholsonanna developingandstrengtheningtheglobalsupplychainforsecondlinedrugsformultidrugresistanttuberculosisworkshopsummary AT instituteofmedicineusforumondrugdiscoverydevelopmentandtranslation developingandstrengtheningtheglobalsupplychainforsecondlinedrugsformultidrugresistanttuberculosisworkshopsummary AT instituteofmedicineusboardonhealthsciencespolicy developingandstrengtheningtheglobalsupplychainforsecondlinedrugsformultidrugresistanttuberculosisworkshopsummary |